FOXO4-DRI
Peptide studied in senescent-cell research models.
Evidence Level
Emerging
Research Type
/ System Mapping
Where this compound appears in research pathways
Research-only note: This mapping is educational and does not represent a treatment protocol.
/ 01
Overview
Peptide studied in senescent-cell research models.
/ 02
Mechanism of Action
Studied for FOXO4-p53 disruption in senescent cells.
/ 03
Research Applications
Senolytic preclinical research.
Studied for, research explores, preclinical models suggest, clinical studies have investigated.
/ 04
Studied Research Contexts
/ 05
Studied Research Dosing Ranges
Limited public data on dosing ranges across research models.
/ 06
Potential Adverse Effects Reported in Research
Adverse effect data is limited. Many compounds in this database lack human safety profiles.
/ 07
Mechanism Deep Dive
FOXO4-DRI is a research peptide designed to disrupt the FOXO4-p53 protein interaction within senescent cells, with the goal of triggering apoptosis selectively in senescent cell populations. Mechanistic data is preclinical.
/ 08
Pathway Role
Sits within the senolytic research pathway at the FOXO4-p53 interaction layer, targeting the senescent cell apoptosis decision point.
/ 09
Biological Targets
/ 10
Research Applications
- Senescent cell clearance preclinical models
- Aging and senolytic mechanism research
/ 11
Evidence Summary
Preclinical only. Not a general-use compound.
Evidence Level Rationale
Rated preclinical due to absence of human controlled trials and its status as a research-stage senolytic.
/ 12
Research Observation Timeline
Early Signal Window
Senescent cell marker shifts within days in preclinical models
Primary Study Window
Days to weeks in preclinical senescence studies
Endpoint Type
Cellular senescence and apoptosis endpoints
Evidence Strength
Preclinical only
/ 13
Safety & Unknowns
Human safety profile is not characterized. Off-target apoptosis and immune consequences are open research questions.
/ 14
Research Limitations
Translation from senescent cell models to human outcome timelines is not established.
/ 15
References
References are being curated from peer-reviewed literature.
/ 07
Evidence Score
Overall Research Confidence
Emerging
Reflects breadth of mechanism, study type, and reproducibility across research literature.
/ 08
Related Peptides
GHK-Cu
Copper-binding tripeptide studied in regenerative biology.
KPV
Tripeptide fragment of α-MSH studied for inflammatory modulation.
Epitalon
Tetrapeptide studied in telomerase/aging research.
Appears in pathways
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.